Targeting EBV-positive B- and T/NK-cell lymphomas
In this issue of Blood, McLaughlin et al demonstrate the safety and efficacy of donor-derived Epstein-Barr virus (EBV) latent membrane protein (LMP)-specific T cells to prevent relapse of aggressive EBV-positive B- or T/NK-cell lymphomas following allogeneic hematopoietic stem cell transplantation (HSCT).1
2002 ◽
Vol 44
(3)
◽
pp. 251-257
◽
2021 ◽
Vol 27
(3)
◽
pp. S338-S339
2016 ◽
Vol 22
(3)
◽
pp. S156-S157
2016 ◽
Vol 34
(19)
◽
pp. 2201-2202
◽